Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Haaland, Benjamin, Chopra, Akhil, Acharyya, Sanchalika, Fay, André P, Lopes, Gilberto de Lima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148555/
https://www.ncbi.nlm.nih.gov/pubmed/25127891
http://dx.doi.org/10.1186/1471-2407-14-592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148555/
https://www.ncbi.nlm.nih.gov/pubmed/25127891
http://dx.doi.org/10.1186/1471-2407-14-592

Ejemplares similares